Thu.May 02, 2024

article thumbnail

CGM Use Linked to Improved Diabetic Retinopathy Outcomes in T1D

Drug Topics

The current study highlights the potential benefit of incorporating continuous glucose monitor (CGM) data into eye care assessments for patients with type 1 diabetes (T1D).

550
550
article thumbnail

$4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’

PharmaVoice

Pricey gene therapies promise great benefit to patients but pose a threat to the payer landscape — ICER and a Tufts think tank are offering potential solutions.

245
245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmacogenetic Testing Recommendations Needed in Clinical Guidelines to Increase Consistency

Drug Topics

A review found that many guidelines that recommended pharmacogenetic testing were inconsistent between clinical associations.

527
527
article thumbnail

Scientists spot an orangutan using a plant to treat his own wound in the wild

STAT

When male Sumatran orangutans let out a long call, they’re usually trying to grab female attention. But the sounds — a booming blend of roars and grunts — can end up attracting unwanted attention from other males, too. Things can get tense. Which is likely how Rakus, an adult male orangutan frequently seen in Gunung Leuser National Park in South Aceh, Indonesia, acquired a face wound in June 2022.

145
145
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Distributors Play a Role in Patient Access Programs

Drug Topics

Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.

Insurance 307
article thumbnail

Bird flu virus circulated in cows for four months before outbreak confirmed by USDA, analysis shows

STAT

As agricultural authorities and epidemiologists try to get their arms around the scope of the latest confounding chapter in the decades-long story of the H5N1 avian influenza virus — its j ump into U.S. herds of dairy cattle — they’re turning to the genetic breadcrumbs the virus leaves behind in the animals’ nose, lungs, and, primarily, milk.

145
145

More Trending

article thumbnail

Tracking bird flu virus changes in cows is stymied by missing data, scientists say

STAT

Another upload of genetic sequence data from the H5N1 bird flu outbreak in dairy cattle has exacerbated the scientific community’s frustration with the U.S. Department of Agriculture after the agency again failed to include basic information needed to track how the virus is changing as it spreads. Like a large tranche of sequences that the USDA uploaded to a public database on April 21, this week’s data dump did not include information about where and when the sequenced samples wer

Labelling 145
article thumbnail

Weight-Loss Drugs Fuel Rise in US Prescription Spending

Drug Topics

The rise of weight-loss drugs has overtaken the US prescription drug market and significantly increased spending from 2022 to 2023.

281
281
article thumbnail

FDA Grants Fast Track Designation to Eneboparatide for Treatment of Patients With Hypoparathyroidism

Pharmacy Times

Currently, the treatment is being evaluated in the phase 3 CALYPSO study to further prove the safety and efficacy in patients with hypoparathyroidism.

FDA 145
article thumbnail

Siloed Systems Hinder Patient Care

Drug Topics

Collaboration between health system specialty pharmacies and manufacturers can benefit patients in the long run.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Expert: Pharmacists Have Vital Role in Multiple Myeloma Treatment

Pharmacy Times

The vice president of pharmacy operations at American Oncology Network says that pharmacists can contribute by educating patients and offering resources for support and treatment adherence.

144
144
article thumbnail

Q&A: Inside the Vanderbilt Specialty Pharmacy-AstraZeneca Collaboration

Drug Topics

A siloed approach to care can worsen patient outcomes, but collaboration between one health system specialty pharmacy and a manufacturer led to better patient care.

article thumbnail

The race for healthcare AI models heats up as Google boasts Med-Gemini surpasses GPT-4

Fierce Healthcare

Google and DeepMind released an open access paper on their newest artificial intelligence tools intended for use in hea | Results released by Google on Med-Gemini's performance show that it outperforms existing AI/ML including GPT-4 on over a dozen industry benchmarks.

143
143
article thumbnail

Real World Data Show That Pharmacist-Manufacturer Collaboration Improves Patient Outcomes

Drug Topics

Collaboration between health system specialty pharmacists and pharmaceutical manufacturers can benefit patients in the long run.

247
247
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: Biological clocks could be the key to longer, healthier lives. But scientists don’t yet agree on what ‘aging’ is

STAT

It’s no secret that a lucky few seem to glide into old age, the years settling gracefully on their bodies, while others appear to have been dragged through time tied to a metaphorical garbage truck. Biologists have been developing numerous ways to measure the rate an individual ages — often called an accelerated or decelerated “biological age” — and trying to translate it into a heightened or reduced risk of the morbidity and mortality that comes with aging.

141
141
article thumbnail

Hurdles In Access: Costly Switch Studies Block Wider Biosimilar Use

Drug Topics

Addressing requirements around FDA interchangeability designations can increase the adoption of biosimilar substitutions at the pharmacy level.

FDA 247
article thumbnail

US Preventive Services Task Force Recommends Breast Cancer Screenings Begin at Age 40

Pharmacy Times

The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.

139
139
article thumbnail

Expert: Biosimilar Legislation Making Moves in the Right Direction

Drug Topics

A recent bill introduced to Congress is intended to prevent product hopping, a practice that extends exclusivity and hinders the adoption of biosimilar therapies.

247
247
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Opinion: Why isn’t there agreement on when women need to start getting mammograms?

STAT

If, after reading the latest recommendation on breast cancer screening by the United States Preventive Services Task Force (USPSTF), you feel like your head is spinning, that’s understandable. The task force’s newest advice , which gives a “B” grade in favor of routine mammograms for women in their 40s, reverses its 2016 statement saying the test should be optional for such women.

134
134
article thumbnail

Compounded, Counterfeit Semaglutide Poses Severe Risk to Patients

Pharmacy Times

Novo Nordisk and Eli Lilly have spoken out against the use of their GLP-1 medications for cosmetic weight loss, emphasizing the proper use of their medications.

article thumbnail

Opinion: The U.S. needs a reliable supply of baby formula. A new bill in Congress can help

STAT

Families in America should never have to scrounge for baby formula. The United States needs a diverse and resilient supply of infant formula. Boosting the ability of smaller companies to compete in this market against the three large formula makers — Abbott, Mead Johnson, and Nestlé Gerber — could help make shortages a thing of the past.

134
134
article thumbnail

NABP Report Explores How Illegal Online Sellers Exploit Consumer Demand for Weight Loss Drugs

Pharmacy Times

This class of drugs, including semaglutide, liraglutide, and tirzepatide, is used to treat type 2 diabetes and obesity.

132
132
article thumbnail

STAT+: Novartis extends radiopharma plans with $1 billion acquisition

STAT

Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these cancer treatments with a new acquisition.  Novartis is paying $1 billion upfront and up to an additional $750 million if certain milestones are met to acquire startup Mariana Oncology, the latter company announced Thursday.

131
131
article thumbnail

Walgreens inks deal with Boehringer Ingelheim to advance clinical trials for obesity treatment

Fierce Healthcare

Retail pharmacy giant Walgreens inked another partnership to recruit participants for research as it continues to build out its clinical trials business. | Walgreens has signed more than 35 clinical trial contracts with drugmakers including Freenome and Prothena. The aim is to optimize recruitment and make clinical trials more accessible, inclusive and equitable, the companies said.

128
128
article thumbnail

STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill

STAT

Amgen said Thursday that it will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate that’s seen as a potential competitor to Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The injectable drug, called MariTide, is in a Phase 2 trial for obesity, and Chief Executive Bob Bradway said on an earnings call that “we are very encouraged with the results” from an interim analysis of that trial.

130
130
article thumbnail

The top pharmaceutical companies by R&D expenditure

Pharmaceutical Technology

From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.

article thumbnail

STAT+: Gilead gets a boost from California court in a case over slow-walking an HIV drug

STAT

In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious legal theory that thousands of HIV patients have used in a closely watched case to argue drugmakers can be held negligent for failing to develop a medicine. Earlier this year, a state appeals court ruled the company could be held liable for halting further development of an HIV medicine that was safer than an HIV drug it was already selling.

article thumbnail

Pace, acceleration, and precision are the name of the game

pharmaphorum

Security and privacy within biotech are critical points of consideration and discussion as the industry continues to innovate at speed, and it is such aspects that are central to today’s podcast with Zach Powers, chief information security officer at Benchling, the R&D cloud platform for the biotech industry.

123
123
article thumbnail

STAT+: Transcarent, Glen Tullman’s health tech unicorn, raises $126 million

STAT

Transcarent, the fast-moving company helmed by health tech investor and former Livongo CEO Glen Tullman, today announced $126 million in Series D funding valuing the company at $2.2 billion. The investment round was led by venture capital giant General Catalyst and 7wireVentures, where Tullman is a managing partner. Transcarent will use the funding to support development of artificial intelligence capabilities across the enterprise, growing its business, and pursuing acquisitions, Tullman told S

128
128
article thumbnail

Expert Discusses Payment Models for Cell and Gene Therapies

Pharmacy Times

Joe DePinto discusses innovative payment models like value-based agreements and warranties for cell and gene therapies

123
123
article thumbnail

STAT+: Novo Nordisk defends Ozempic’s price in face of Senate scrutiny

STAT

Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy amid a Senate probe into what the company charges. Speaking on an earnings call Thursday, CEO Lars Fruergaard Jørgensen said the company launched the treatments at similar prices to earlier generations in the drug class, despite their having greater efficacy, making them “an attractive value proposition.

125
125
article thumbnail

Long-acting antibody demonstrates promising efficacy in infant RSV

European Pharmaceutical Review

Interim results of an ongoing study published in The Lancet have reported that Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalisations by 82 percent in infants under six months, compared to infants who received no RSV intervention. Sanofi noted that as a long-acting antibody, Beyfortus has been shown to provide rapid protection, helping to prevent lower respiratory tract disease caused by RSV without the immune system needing activation.

Hospitals 122
article thumbnail

Cigna posts $277M loss in the first quarter of 2024

Fierce Healthcare

The Cigna Group posted a $277 million loss in Q1 on the back of investment losses, according to its earnings report released Thursday. | The Cigna Group posted a $277 million loss in Q1 on the back of investment losses, according to its earnings report released Thursday.

121
121